Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Patent
1997-10-30
1999-12-07
Pak, John
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
424 43, 424450, 424600, 514 6, 514 8, 514 37, 514184, 514253, 514255, 514354, 514492, 514669, 514851, A61K 3128, A61K 3324, A61K 3840
Patent
active
059979127
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to the treatment of infections caused by intracellular pathogens, such as M. tuberculosis and others and to pathogens that cause chronic pulmonary infections. In particular, this invention relates to methods for inhibiting the growth of intracellular pathogens and pathogens causing chronic pulmonary infections using gallium-containing compounds, and to methods to test the capacity of these compounds to inhibit growth of these pathogens in mononuclear phagocytes.
BACKGROUND OF THE INVENTION
This invention was made with government support under agreement numbers AI33004 and AI34954 awarded by the National Institutes of Health. The government has certain rights to this invention.
Intracellular pathogens include, but are not limited to, Mycobacteria species including M. tuberculosis, M. avium-intracellulare (MAI), and other intracellular pathogens including Legionella pneumophila, Histoplasma capsulatum, Leishmania species including L. chagasi, L. donovani and L. major, and the like. These organisms are characterized by their ability to be phagocytosed and sequestered in macrophages in patients infected with these organisms. In general, intracellular sequestration makes these organisms more difficult to treat with standard anti-bacterial therapies.
Tuberculosis is caused principally by the pathogenic agent Mycobacterium tuberculosis (M. tuberculosis) and more rarely by M. bovis or M. africanum. M. tuberculosis is an exemplary intracellular pathogen in that it, like other intracellular pathogens is phagocytosed in vivo by mononuclear phagocytes and becomes sequestered and/or grows within the phagocytic cell. Tuberculosis continues to be a major cause of worldwide morbidity and mortality, especially in the elderly and in immunocompromised patients, such as HIV(human immunodeficiency virus)-infected persons. The World Health Organization estimates that 1.7 billion persons, or one third of the world's population, are infected with tuberculosis. New estimates indicate that there are approximately 10 million new cases of tuberculosis annually with three million deaths associated with tuberculosis worldwide.
The only current vaccine for M. tuberculosis is the BCG vaccine. This vaccine is a live attenuated strain of Mycobacterium bovis. The vaccine produces variable results and may rarely initiate active tuberculosis infection in compromised vaccinees. A significant problem associated with the vaccine is that it results in the conversion of the tuberculin skin test (PPD) from negative to positive. The tuberculin skin test is still the primary test of choice for diagnosing exposure to M. tuberculosis. Therefore, individuals receiving the BCG vaccine test positive using the tuberculin skin test making patient monitoring for M. tuberculosis exposure more difficult. Until such time that a uniformly effective vaccine exists, novel therapeutic approaches that significantly reduce the duration of therapy will have a major impact on compliance and ultimately on the transmission of this disease.
Current therapies to treat tuberculosis are becoming less satisfactory because of a growing incidence of drug-resistant strains of M. tuberculosis. Effective therapy for active tuberculosis requires multiple types of antibiotics taken for a minimum of six months. Each of these antibiotics causes sizable morbidity from drug toxicity. Further, poor compliance, in part due to the duration of treatment and side effects of the antibiotics, remains a critical issue in the treatment of tuberculosis. Improper treatment of M. tuberculosis infection has led directly to a growing incidence of multi-drug resistant tuberculosis leading to prolonged infectiousness and thereby enhanced transmission potential.
MAI is the most common mycobacterial pathogen in AIDs patients. Up to 50% of this population will develop infection due to MAI in their lifetime. MAI are inherently multi-drug resistant and treatment for these patients currently requires taking multiple types of antibiotics for life. Infections d
REFERENCES:
patent: 5175006 (1992-12-01), Matkovic et al.
patent: 5525598 (1996-06-01), Collery et al.
patent: 5747482 (1998-05-01), Bernstein
patent: 5877210 (1999-03-01), Schieven
patent: 5883088 (1999-03-01), Bernstein
C. R. Chitambar et al., "Inhibition of Ribonucleotide Reductase by Gallium in Murine Leukemic L1210 Cells," Cancer Research, 51:6199-6201 (1991).
Chemical Abstract 79:122276 (1973).
Chemical Abstract 89: 141068 (1978).
Chemical Abstract 79: 122497 (1973).
Chemical Abstract 109: 236917 (1988).
R. Ankenbauer et al., "Effects of Siderophores on the Growth of Pseudomonas aeruginosa in Human Serum and Transferrin", Infect. Imm., 49 132-140 (1985).
V. Balasubramanian et al., "Growth Characteristics of Recent Sputum Isolates of Mycobacterium tuberculosis in Guinea Pigs Infected by the Respiratory Route", Infect. Imm., 60 4762-4767 (1992).
V. Balasubramanian et al., "Mycobacterial Infection in Guinea Pigs", Immunobiol., 191 395-401 (1994).
H. Bouissou et al., "Effect of gallium sulfate on cellular immunity," Comptes Rendus Acad. Sci., Ser. D., 276(21), 2915-2918 (1973).
T.F. Byrd et al., "Interferon Gamma-activated Human Monocytes Downregulate Transferrin Receptors and Inhibit the Intracellular Multiplication of Legionella pneumophila by Limiting the Availability of Iron", J. Clin. Invest., 83 1457-1465 (1989).
T.F. Byrd et al., "Regulation of Transferrin Receptor Expression and Ferritin Content in Human Mononuclear Phagocytes", J. Clin. Invest., 91 969-976 (1993).
S.J. Cavalieri et al., "Synergistic Activities of Clarithromycin and Antituberculous Drugs against Multidrug-Resistant Mycobacterium tuberculosis", Antimicrobial Agents and Chemotherapy, 39 1542-1545 (1995).
V. Challu et al., "Recovery of Tubercle Bacilli From Urine of Pulmonary Tuberculosis Patients and its Comparison with the Corresponding Sputum Isolates", Ind. J. Tub., 36 107-111 (1989).
C.R. Chitambar et al., "Inhibition of Leukemic HL60 Cell Growth by Transferrin-Gallium: Effects on Ribonucleotide Reductase and Demonstration of Drug Synergy With Hydroxyurea", Blood, 72 1930-1936 (1988).
C.R. Chitambar et al., "Regulatory Effects of Gallium on Transferrin-Independent Iron Uptake by Human Leukemic HL60 Cells", Blood, 80 505-511 (1992).
C.R. Chitambar et al., "Effects of Different Transferrin Forms on Transferrin Receptor Expression, Iron Uptake, and Cellular Proliferation of Human Leukemic HL60 Cells", J. Clin. Invest., 78 1538-1546 (1986).
C.R. Chitambar et al., "Uptake of Gallium-67 by Human Leukemic Cells: Demonstration of Transferrin Receptor-dependent and Transferrin-independent Mechanisms", Cancer Research, 47 3929-3934 (1987).
P.H. Collery et al., "Dose Optimization of Gallium Chloride, Orally Administered, in Combination with Platinum Compounds", Anticancer Research, 14 2299-2306 (1994).
C.D. Cox, "Role of Pyocyanin in the Acquisition of Iron from Transferrin", Infect. Immun., 52 263-270 (1986).
G.S. Douvas et al., "Gamma Interferon Activates Human Macrophages to Become Tumorcidal and Leishmanicidal but Enhances Replication of Macrophage--Associated Mycobacteria", Infect. Immun., 50 1-8 (1985).
G.S. Douvas et al., "Hypertriglyceridemic Serum, Very Low Density Lipoprotein, and Iron Enhance Mycobacterium avium Replication in Human Macrophages", J. Infect. Dis., 170 1248-1255 (1994).
R.B. Fick, Jr., "Pathogenesis of the Pseudomonas Lung Lesion in Cystic Fibrosis", Chest, 96 158-164 (1989).
R.A. Finkelstein, et al., "Role of Iron in Microbe-Host Interactions", Rev. Infect. Dis., 5, Suppl. 4, S759-S777 (1983).
B. Foster et al., "Gallium Nitrate: The Second Metal With Clinical Activity", Cancer Treatment Rep., 70 1311-1319 (1986).
S.K. Furney et al., "Activities of Rifabutin, Clarithromycin, and Ethambutol against Two Virulent Strains of Mycobacterium avium in a Mouse Model", Antimicrobial Agents and Chemotherapy, 39 786-789 (1995).
P. Gangadharam et al., "Therapy of Mycobacterium aviam Complex Infections in Beige Mice with Streptomycin Encapsulated in Sterically Stabilized Lipos
Britigan Bradley E.
Schlesinger Larry S.
Pak John
University of Iowa Research Foundation
LandOfFree
Method for inhibiting growth of P. aeruginosa using gallium-cont does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting growth of P. aeruginosa using gallium-cont, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting growth of P. aeruginosa using gallium-cont will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-820905